FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2546286880> ?p ?o ?g. }

• W2546286880 endingPage "1374" @default.
• W2546286880 startingPage "1374" @default.
• W2546286880 abstract "Fatal metastatic relapse may occur in children with retinoblastoma and high-risk pathologic features (HRPFs). Minimal dissemination (MD) may be an additional tool for risk estimation. The use of cone-rod homeobox (CRX) transcription factor messenger RNA for MD evaluation in metastatic retinoblastoma was previously reported, but no data in nonmetastatic cases with HRPFs are available.To evaluate whether MD is detectable in patients with nonmetastatic retinoblastoma and to assess its prognostic effect on disease-free survival (DFS).This single-institution cohort study of patients with nonmetastatic retinoblastoma and HRPFs used prospectively defined inclusion criteria and a sampling strategy to procure bone marrow (BM) and cerebrospinal fluid (CSF) samples from May 1, 2007, through October 31, 2013. Median follow-up was 38 months (range, 8-89 months). Survival analysis was closed in December 2015, and no further updates were made after that point.The study evaluated CRX messenger RNA by quantitative polymerase chain reaction in BM and CSF at diagnosis and follow-up. In 14 patients, GD2 synthase was used instead of CRX for CSF evaluation. Patients were treated under uniform guidelines.Metastatic relapse.The study included 96 children (median age at study inclusion, 26 months; range, 1-168 months; 46 male [47.9%]; 50 female [52.1%]) with nonmetastatic retinoblastoma and HRPFs (isolated massive choroidal invasion in 14, postlaminar optic nerve invasion in 51 [26 with concomitant massive choroidal and 13 with scleral invasion], 12 with scleral invasion without postlaminar optic nerve invasion, and 7 with tumor at the resection margin of the optic nerve) were evaluated at the time of primary or secondary enucleation. Minimal dissemination was detected in 9 patients (7 BM samples and 2 CSF samples) and was associated with extension beyond the resection margin of the optic nerve and scleral involvement, but only the former was independently associated (adjusted odds ratio, 57.0; 95% CI, 4.8-678.2; P = .001). In addition, MD occurred in 8 of the 43 International Intraocular Retinoblastoma Classification group E eyes with glaucoma (18.6%) and in 8 of 80 (10%) and 1 of 16 children (6.3%) who underwent primary or secondary enucleation, respectively. Children with MD had a 3-year DFS of 0.78 compared with 0.98 in those without MD (95% CI for the difference in DFS, 0.17-0.23; P = .004).These findings identified a high-risk population of children with retinoblastoma and HRPFs with MD. Because the number of events was small, these results, which suggest that children with International Intraocular Retinoblastoma Classification group E retinoblastoma and glaucoma have a higher risk of MD at diagnosis, should not be considered definitive at this time." @default.
• W2546286880 created "2016-11-04" @default.
• W2546286880 creator A5006705477 @default.
• W2546286880 creator A5013211246 @default.
• W2546286880 creator A5031833191 @default.
• W2546286880 creator A5032519145 @default.
• W2546286880 creator A5040263125 @default.
• W2546286880 creator A5044891322 @default.
• W2546286880 creator A5047922221 @default.
• W2546286880 creator A5053775464 @default.
• W2546286880 creator A5068999895 @default.
• W2546286880 creator A5079691260 @default.
• W2546286880 creator A5083385228 @default.
• W2546286880 creator A5090116111 @default.
• W2546286880 date "2016-12-01" @default.
• W2546286880 modified "2023-10-10" @default.
• W2546286880 title "Minimal Disseminated Disease in Nonmetastatic Retinoblastoma With High-Risk Pathologic Features and Association With Disease-Free Survival" @default.
• W2546286880 cites W1844379777 @default.
• W2546286880 cites W1902808961 @default.
• W2546286880 cites W1969742959 @default.
• W2546286880 cites W1970615351 @default.
• W2546286880 cites W1981435453 @default.
• W2546286880 cites W1983078166 @default.
• W2546286880 cites W2001679469 @default.
• W2546286880 cites W2001790441 @default.
• W2546286880 cites W2025712151 @default.
• W2546286880 cites W2031050159 @default.
• W2546286880 cites W2044498114 @default.
• W2546286880 cites W2053492058 @default.
• W2546286880 cites W2061395283 @default.
• W2546286880 cites W2071678800 @default.
• W2546286880 cites W2073029275 @default.
• W2546286880 cites W2097298290 @default.
• W2546286880 cites W2097779206 @default.
• W2546286880 cites W2098473106 @default.
• W2546286880 cites W2108205471 @default.
• W2546286880 cites W2112934711 @default.
• W2546286880 cites W2113613548 @default.
• W2546286880 cites W2118821887 @default.
• W2546286880 cites W2130230865 @default.
• W2546286880 cites W2150700030 @default.
• W2546286880 cites W2151968921 @default.
• W2546286880 cites W2163814095 @default.
• W2546286880 cites W2179125514 @default.
• W2546286880 cites W2326754298 @default.
• W2546286880 cites W2497721881 @default.
• W2546286880 doi "https://doi.org/10.1001/jamaophthalmol.2016.4158" @default.
• W2546286880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27787537" @default.
• W2546286880 hasPublicationYear "2016" @default.
• W2546286880 type Work @default.
• W2546286880 sameAs 2546286880 @default.
• W2546286880 citedByCount "18" @default.
• W2546286880 countsByYear W25462868802017 @default.
• W2546286880 countsByYear W25462868802018 @default.
• W2546286880 countsByYear W25462868802019 @default.
• W2546286880 countsByYear W25462868802020 @default.
• W2546286880 countsByYear W25462868802021 @default.
• W2546286880 countsByYear W25462868802022 @default.
• W2546286880 countsByYear W25462868802023 @default.
• W2546286880 crossrefType "journal-article" @default.
• W2546286880 hasAuthorship W2546286880A5006705477 @default.
• W2546286880 hasAuthorship W2546286880A5013211246 @default.
• W2546286880 hasAuthorship W2546286880A5031833191 @default.
• W2546286880 hasAuthorship W2546286880A5032519145 @default.
• W2546286880 hasAuthorship W2546286880A5040263125 @default.
• W2546286880 hasAuthorship W2546286880A5044891322 @default.
• W2546286880 hasAuthorship W2546286880A5047922221 @default.
• W2546286880 hasAuthorship W2546286880A5053775464 @default.
• W2546286880 hasAuthorship W2546286880A5068999895 @default.
• W2546286880 hasAuthorship W2546286880A5079691260 @default.
• W2546286880 hasAuthorship W2546286880A5083385228 @default.
• W2546286880 hasAuthorship W2546286880A5090116111 @default.
• W2546286880 hasBestOaLocation W25462868801 @default.
• W2546286880 hasConcept C104317684 @default.
• W2546286880 hasConcept C118487528 @default.
• W2546286880 hasConcept C126322002 @default.
• W2546286880 hasConcept C141071460 @default.
• W2546286880 hasConcept C142724271 @default.
• W2546286880 hasConcept C143998085 @default.
• W2546286880 hasConcept C185592680 @default.
• W2546286880 hasConcept C2776577112 @default.
• W2546286880 hasConcept C2779384505 @default.
• W2546286880 hasConcept C2780837183 @default.
• W2546286880 hasConcept C55493867 @default.
• W2546286880 hasConcept C71924100 @default.
• W2546286880 hasConceptScore W2546286880C104317684 @default.
• W2546286880 hasConceptScore W2546286880C118487528 @default.
• W2546286880 hasConceptScore W2546286880C126322002 @default.
• W2546286880 hasConceptScore W2546286880C141071460 @default.
• W2546286880 hasConceptScore W2546286880C142724271 @default.
• W2546286880 hasConceptScore W2546286880C143998085 @default.
• W2546286880 hasConceptScore W2546286880C185592680 @default.
• W2546286880 hasConceptScore W2546286880C2776577112 @default.
• W2546286880 hasConceptScore W2546286880C2779384505 @default.
• W2546286880 hasConceptScore W2546286880C2780837183 @default.
• W2546286880 hasConceptScore W2546286880C55493867 @default.
• W2546286880 hasConceptScore W2546286880C71924100 @default.
• W2546286880 hasIssue "12" @default.

• next